Literature DB >> 24812602

Decoding hepatocellular carcinoma: the promise of microRNAs.

Fyza Shaikh1, Laura W Goff1.   

Abstract

MicroRNAs (miRNAs) may play an important role in the development and progression of hepatocellular carcinoma (HCC). Understanding the mechanism of specific miRNAs may provide opportunity for development of biomarkers and novel therapeutics in hepatocellular carcinoma which are desperately needed.

Entities:  

Keywords:  Hepatocellular carcinoma (HCC); MET; hepatocyte growth factor (HGF); microRNAs (miRNAs); vascular endothelial growth factor (VEGF)

Year:  2014        PMID： 24812602      PMCID： PMC3999426          DOI： 10.3978/j.issn.2304-3881.2014.02.08

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN： 2304-3881            Impact factor:   7.293


  8 in total

1.  MicroRNA-26a suppresses angiogenesis in human hepatocellular carcinoma by targeting hepatocyte growth factor-cMet pathway.

Authors:  Xin Yang; Xiao-Fei Zhang; Xu Lu; Hu-Liang Jia; Lei Liang; Qiong-Zhu Dong; Qing-Hai Ye; Lun-Xiu Qin
Journal:  Hepatology       Date:  2014-04-01       Impact factor: 17.425

2.  MicroRNA-26a suppresses tumor growth and metastasis of human hepatocellular carcinoma by targeting interleukin-6-Stat3 pathway.

Authors:  Xin Yang; Lei Liang; Xiao-Fei Zhang; Hu-Liang Jia; Yi Qin; Xu-Chao Zhu; Xiao-Mei Gao; Peng Qiao; Yan Zheng; Yuan-Yuan Sheng; Jin-Wang Wei; Hai-Jun Zhou; Ning Ren; Qing-Hai Ye; Qiong-Zhu Dong; Lun-Xiu Qin
Journal:  Hepatology       Date:  2013-06-05       Impact factor: 17.425

3.  Identification of metastasis-related microRNAs in hepatocellular carcinoma.

Authors:  Anuradha Budhu; Hu-Liang Jia; Marshonna Forgues; Chang-Gong Liu; David Goldstein; Amy Lam; Krista A Zanetti; Qing-Hai Ye; Lun-Xiu Qin; Carlo M Croce; Zhao-You Tang; Xin Wei Wang
Journal:  Hepatology       Date:  2008-03       Impact factor: 17.425

4.  Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.

Authors:  Josep M Llovet; Thomas Decaens; Jean-Luc Raoul; Eveline Boucher; Masatoshi Kudo; Charissa Chang; Yoon-Koo Kang; Eric Assenat; Ho-Yeong Lim; Valerie Boige; Philippe Mathurin; Laetitia Fartoux; Deng-Yn Lin; Jordi Bruix; Ronnie T Poon; Morris Sherman; Jean-Frédéric Blanc; Richard S Finn; Won-Young Tak; Yee Chao; Rana Ezzeddine; David Liu; Ian Walters; Joong-Won Park
Journal:  J Clin Oncol       Date:  2013-08-26       Impact factor: 44.544

5.  Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study.

Authors:  Philip J Johnson; Shukui Qin; Joong-Won Park; Ronnie T P Poon; Jean-Luc Raoul; Philip A Philip; Chih-Hung Hsu; Tsung-Hui Hu; Jeong Heo; Jianming Xu; Ligong Lu; Yee Chao; Eveline Boucher; Kwang-Hyub Han; Seung-Woon Paik; Jorge Robles-Aviña; Masatoshi Kudo; Lunan Yan; Abhasnee Sobhonslidsuk; Dmitry Komov; Thomas Decaens; Won-Young Tak; Long-Bin Jeng; David Liu; Rana Ezzeddine; Ian Walters; Ann-Lii Cheng
Journal:  J Clin Oncol       Date:  2013-08-26       Impact factor: 44.544

6.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

7.  Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial.

Authors:  Ann-Lii Cheng; Yoon-Koo Kang; Deng-Yn Lin; Joong-Won Park; Masatoshi Kudo; Shukui Qin; Hyun-Cheol Chung; Xiangqun Song; Jianming Xu; Guido Poggi; Masao Omata; Susan Pitman Lowenthal; Silvana Lanzalone; Liqiang Yang; Maria Jose Lechuga; Eric Raymond
Journal:  J Clin Oncol       Date:  2013-09-30       Impact factor: 44.544

8.  Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.

Authors:  Armando Santoro; Lorenza Rimassa; Ivan Borbath; Bruno Daniele; Stefania Salvagni; Jean Luc Van Laethem; Hans Van Vlierberghe; Jörg Trojan; Frank T Kolligs; Alan Weiss; Steven Miles; Antonio Gasbarrini; Monica Lencioni; Luca Cicalese; Morris Sherman; Cesare Gridelli; Peter Buggisch; Guido Gerken; Roland M Schmid; Corrado Boni; Nicola Personeni; Ziad Hassoun; Giovanni Abbadessa; Brian Schwartz; Reinhard Von Roemeling; Maria E Lamar; Yinpu Chen; Camillo Porta
Journal:  Lancet Oncol       Date:  2012-11-20       Impact factor: 41.316
  8 in total
  2 in total

1.  MiR-141 targets ZEB2 to suppress HCC progression.

Authors:  Shi-Min Wu; Hong-Wu Ai; Ding-Yu Zhang; Xiao-Qun Han; Qin Pan; Feng-Ling Luo; Xiao-Lian Zhang
Journal:  Tumour Biol       Date:  2014-07-10

Review 2.  The "Macro" World of microRNAs in Hepatocellular Carcinoma.

Authors:  Kaveri Sidhu; Neetu Rohit Kapoor; Vijaya Pandey; Vijay Kumar
Journal:  Front Oncol       Date:  2015-03-25       Impact factor: 6.244
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.